Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06446739

LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)

Led by University of Alberta · Updated on 2026-04-28

100

Participants Needed

9

Research Sites

132 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

An estimated 10-15% of critically ill patients with acute kidney failure in the intensive care unit receive acute dialysis therapy. The majority of these patients initially receive a continuous form of dialysis therapy call continuous renal replacement therapy (CRRT). Prior studies have suggested that higher CRRT dose-intensity improved health outcomes for these patients; however, this was not found in high-quality clinical trials. These more recent trials suggested a lower range of dose-intensity compared with the higher range as the new standard of care. This was incorporated into guidelines. To date, no clinical trials have evaluated this lower range and specifically, it is plausible that an even lower dose-intensity of CRRT may be well tolerated, safe, associated with similar outcomes and be more cost-effective. This is the objective of the WISDOM trial, to compare the guideline standard with lower dose-intensity among patients who are started on CRRT in the intensive care unit.

CONDITIONS

Official Title

LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Weight 55 kg or more
  • Plan to start CRRT or started CRRT within the last 24 hours for acute kidney injury
  • Expected to survive and receive CRRT for at least 48 hours
  • Able to provide informed consent or have an authorized representative provide consent
Not Eligible

You will not qualify if you...

  • Need for sustained higher dose-intensity CRRT as determined by treating clinicians
  • End-stage kidney disease on maintenance dialysis
  • Received any renal replacement therapy for acute kidney injury during current hospital stay
  • Unable to follow study protocol requirements

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

Mayo Clinic

Rochester, Minnesota, United States, 55905

Actively Recruiting

2

University of Alberta Hospital

Edmonton, Alberta, Canada, T6G 2B7

Actively Recruiting

3

Grey Nuns Hospital

Edmonton, Alberta, Canada

Actively Recruiting

4

Sturgeon Community Hospital

St. Albert, Alberta, Canada, T8N 6C4

Actively Recruiting

5

Hamilton General Hospital

Hamilton, Ontario, Canada

Actively Recruiting

6

Sunnybrook Health Sciences Centre

North York, Ontario, Canada, M4N 3M5

Actively Recruiting

7

St Michael's Hospital

Toronto, Ontario, Canada

Actively Recruiting

8

Regina General Hospital/Saskatchewan Health Authority

Regina, Saskatchewan, Canada

Actively Recruiting

9

Guy's & St Thomas' Hospitals

London, United Kingdom, SE1 9RT

Actively Recruiting

Loading map...

Research Team

S

Sean M Bagshaw, MD

CONTACT

E

Ellen Morrison, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here